There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but ...

In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as ...

UK-based electronRx will launch a digital health technology (DHT) to help patients with respiratory disease manage their ...

The importance of AI in pharma and life sciences cannot be overstated. Regardless of the aspect of industry you examine, ...

Novo Nordisk is also ahead in the race to bring an oral GLP-1 to market for weight loss, as it has already filed semaglutide for FDA approval, with a decision before the end of this year, while Lilly ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing ...

The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

Dr Susan Monarez told lawmakers today that Health and Human Services (HHS) Secretary Robert F Kennedy Jr said he planned to ...

AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for ...

Novo Nordisk's letter refers to the same Oprah Winfrey show and its GLP-1 weight-loss drug Wegovy (semaglutide), while CSL ...